Amin Haiderali
6PUBLICATIONS
24CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.Hope S Rugo, David W Cescon, Mark E Robson
|Apr 10, 2024
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.Amin Haiderali, Min Huang, Wilbur Pan
|Aug 21, 2023
Association between event-free survival and overall survival in early-stage triple-negative breast cancer.Min Huang, Peter A Fasching, Amin Haiderali
|Jul 07, 2022
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.Min Huang, Peter Fasching, Amin Haiderali
|Jul 13, 2021
Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer.Amin Haiderali, Whitney C Rhodes, Santosh Gautam
|Jul 06, 2021
Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.Amin Haiderali, Whitney C Rhodes, Santosh Gautam
Pageof 1
Frequent Collaborators
2 joint publications
Whitney C Rhodes
2 joint publications
Karen E Skinner
1 joint publications
Weiguang Xue
1 joint publications
Katherine G Akers
1 joint publications
Hope S Rugo
1 joint publications
David W Cescon
1 joint publications
Mark E Robson
1 joint publications
Seock-Ah Im
1 joint publications
Florence Dalenc
1 joint publications
Eduardo Yañez Ruiz
